Ribeirão Preto School of Medicine, Department of Gynecology and Obstetrics, Gynecologic Oncology and Breast Disease Division, University of São Paulo, Ribeirão Preto, São Paulo, Brazil.
Advanced Research Center in Medicine, Union of the Colleges of the Great Lakes (UNILAGO), São José do Rio Preto, São Paulo, Brazil.
JCO Glob Oncol. 2021 Jan;7:81-88. doi: 10.1200/GO.20.00440.
Breast cancer screening is not recommended for young women (< 40 years old); therefore, those diagnosed are more likely to have advanced and metastatic disease, reducing treatment outcomes. This study aimed to investigate breast cancer epidemiology among young women in Brazil.
Data from three publicly available databases and a cohort from a university hospital in Brazil were analyzed in a retrospective study. Descriptive statistics was performed on disease prevalence and stage distribution across age groups. Incidence was estimated using age-standardized incidence ratio. The impact of age in disease-specific survival was also analyzed.
Invasive breast cancer prevalence data by age group revealed that 4.4% and 20.6% of patients were < 35 and < 45 years old, respectively. In the United States, this prevalence was 1.85% and 11.5%, respectively (odds ratio [OR], 2.2; < .0001). The percentage of regional and metastatic diseases were higher in São Paulo State (Fundação Oncocentro de São Paulo [FOSP]) compared with the United States (45% and 9.8% 29% and 5.7%, respectively; < .0001). In FOSP, regional and metastatic disease prevalence were higher among young patients (53.5% and 11.3%, respectively). The median tumor size in patients < 40 years old was higher (25.0 mm × 20.9 mm; < .0001), and young patients have higher risk to be diagnosed with positive lymph nodes (OR, 1.5; = .004) and higher proportion of luminal-B and triple-negative (TNBC) tumors. Young patients have a poor disease-specific survival because of late-stage diagnosis and more aggressive breast cancer subtypes (human epidermal growth factor receptor 2-enriched and TNBC) ( < .0001).
In Brazil, breast cancer prevalence among young patients and late-stage incidence during this age span is higher. Advanced disease and more aggressive subtypes lead to a significant impact on breast cancer-specific survival in young patients.
不建议对年轻女性(<40 岁)进行乳腺癌筛查;因此,这些年轻女性确诊时更有可能患有晚期和转移性疾病,从而降低治疗效果。本研究旨在调查巴西年轻女性的乳腺癌流行病学。
本回顾性研究分析了来自巴西三个公开数据库的数据以及一家大学医院的队列数据。对不同年龄组的疾病流行率和分期分布进行描述性统计。使用年龄标准化发病率比估计发病率。还分析了年龄对疾病特异性生存率的影响。
按年龄组划分的浸润性乳腺癌患病率数据显示,分别有 4.4%和 20.6%的患者<35 岁和<45 岁。而在美国,这一比例分别为 1.85%和 11.5%(比值比[OR],2.2;<0.0001)。与美国相比,圣保罗州(圣保罗肿瘤中心基金会[FOSP])的局部和转移性疾病比例更高(45%和 9.8%,29%和 5.7%;<0.0001)。在 FOSP,年轻患者中局部和转移性疾病的患病率更高(分别为 53.5%和 11.3%)。<40 岁患者的肿瘤平均大小更高(25.0 毫米×20.9 毫米;<0.0001),并且年轻患者被诊断为阳性淋巴结的风险更高(OR,1.5;=0.004),以及更高比例的管腔 B 型和三阴性(TNBC)肿瘤。年轻患者的疾病特异性生存率较差,原因是诊断较晚和更具侵袭性的乳腺癌亚型(人表皮生长因子受体 2 过表达和 TNBC)(<0.0001)。
在巴西,年轻患者的乳腺癌患病率以及该年龄段的晚期发病率较高。晚期疾病和更具侵袭性的亚型对年轻患者的乳腺癌特异性生存率产生重大影响。